Vasudev Magaji, MD
Endocrinology, Diabetes & Metabolism · Wilkes Barre, PANPI 1750589735
Payments from drug & device makers
Across 212 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$550
- Lilly USA, LLC$477
- Xeris Pharmaceuticals, Inc.$382
- Abbott$337
- Boehringer Ingelheim$310
- Mannkind Corporation$287
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,76498%
- Education$100%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $550 |
| Lilly USA, LLC | 31 | $477 |
| Xeris Pharmaceuticals, Inc. | 22 | $382 |
| Abbott | 26 | $337 |
| Boehringer Ingelheim | 11 | $310 |
| Mannkind Corporation | 16 | $287 |
| Medtronic | 8 | $156 |
| Amgen(2 entities) | 7 | $145 |
| Kyowa Kirin, Inc. | 4 | $96 |
| Dexcom, Inc. | 6 | $95 |
| Ascensia Diabetes Care US Inc. | 5 | $95 |
| IBSA Pharma Inc. | 5 | $94 |
| Tandem Diabetes Care, Inc. | 3 | $89 |
| Insulet Corporation | 4 | $72 |
| Bayer | 3 | $65 |
| Cequr Corporation | 1 | $63 |
| Corcept Therapeutics | 4 | $63 |
| BD | 2 | $49 |
| AstraZeneca(2 entities) | 3 | $48 |
| Embecta Corp. | 2 | $39 |
| Senseonics, Incorporated | 1 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| BETA Bionics, Inc. | 3 | $30 |
| Amphastar Pharmaceuticals, Inc. | 2 | $30 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Merck | 1 | $18 |
| Sandoz | 1 | $17 |
| Novartis | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$124
How this compares
$3,833 in reported general payments places this provider in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $189,237 |
| MounjaroTirzepatide | 99 | $102,380 |
| TrulicityDulaglutide | 79 | $78,169 |
| JardianceEmpagliflozin | 96 | $65,137 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $52,310 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $47,014 |
| FarxigaDapagliflozin Propanediol | 61 | $38,548 |
| TymlosAbaloparatide | 12 | $30,915 |
| TradjentaLinagliptin | 52 | $30,357 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $16,874 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $12,865 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 11 | $11,698 |
| Novolog FlexpenInsulin Aspart | 64 | $10,595 |
| KerendiaFinerenone | 15 | $9,571 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $9,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $550 | $192,435195 claims |
| Lilly USA, LLCMounjaro, Trulicity, Baqsimi | $477 | $186,552191 claims |
| Boehringer IngelheimJardiance, Tradjenta | $310 | $95,494148 claims |
| AstraZenecaFarxiga | $48 | $38,54861 claims |
| BayerKerendia | $65 | $9,57115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Wilkes Barre
- Brian JamesonWilkes Barre$64K
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.